Q3 2025

5 Stocks Set to DOUBLE

ZACKS | Our Research. Your Success.

Contents

Overview

Thank you for your interest in Zacks and our *5 Stocks Set to Double* Special Report, featuring picks favored by our experts to gain +100% and more in the months ahead. Each starts off with the Zacks Rank, our quantitative stock-rating system that has more than doubled the S&P 500 with an average gain of +23.8% per year from January 1, 1988 to July 7, 2025. So not only are they poised to climb high, but also expected to start fast.

While we can't guarantee future success, previous editions of this report have racked up gains of **+112%**, **+171%**, and **+209%.**[1]

Each of the five stocks in this report was handpicked by one of our stock strategists, who explain their rationale in the included stock write-ups Clearly, this report was not written for the risk-averse or conservative investor. Rather, these stocks are for the aggressive investor looking to add home-run potential to his or her portfolio. It would be prudent to devote no more than a small portion of your overall portfolio to these stocks.

That said, we hardly threw darts at a board to arrive at these choices. Each stock has catalysts we think could fuel strong gains over the coming year. We sifted through stocks that met Zacks Rank criteria and then chose the crème de la crème. Each of the five stocks has unique qualities that make it a candidate for this report. And they are all from different sectors, offering a level of diversification even in a small sample like this one.

Most of the stocks in this report are currently flying under the radar of most Wall Street analysts and traders, which provides a good opportunity to get in on the ground floor. The market is littered with these kinds of stocks, but only the ones with positive catalysts on the horizon burst onto the scene with monstrous gains. We made sure that we could identify specific factors that would bring these stocks out from obscurity and onto the lists of top performing stocks.

My Personal Favorite

These are all interesting investing ideas that should outperform the market, though I am partial towards Kevin Cook's **Intellia Therapeutics (NTLA)**. Based in Cambridge, MA, it is a clinical stage gene-editing company that is developing highly prospective therapies for two rare diseases. We appear to be in the very early stages of investors starting to appre- ciate the full potential of Intellia's product pipeline. This has helped the stock roughly double in recent months, but it still remains significantly below its all-time high during Covid. The improving sentiment on Intellia and the stock's recent performance gives me confidence that the stock is well positioned to double over the coming year.

Best regards,

Sheraz Mian
Director of Research

Intellia Therapeutics, Inc.

I've been a CRISPR investor for eight years. In that time, there have been numerous rounds of extreme optimism and pessimism that took stocks like CRSP and NTLA to great heights and crushing lows.

It's quite possible that we are now witnessing a final round of lows before clinical and commercial successes are about to become significant tailwinds.

And I think **Intellia (NTLA)** may have significant upside after building a 7-month base between $6 and $12, with the average analyst price target at $38 and pipeline advances bearing fruit.

What CRISPR Magic Awaits?

Recall that CRISPR (Clustered Regularly-Interspaced Short Palindromic Repeats) is a gene editing platform that uses the billion-year-old technology of bacteria to rearrange the DNA of attacking viruses.

Intellia is leveraging its CRISPR modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need.

NTLA's leads in vivo product candidates are nex-z (formerly NTLA-2001) for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of hereditary angioedema.

ATTR amyloidosis is a rare, progressive disease caused by the buildup of misfolded transthyretin (TTR) protein in various organs and tissues. This buildup, called amyloid deposits, can affect the heart, nerves, kidneys, eyes, and gastrointestinal tract. There are two main types: hereditary (familial) and wild-type (age-related). Symptoms and age of onset vary, but can include heart failure, nerve damage (neuropathy), and gastrointestinal issues.

Meet Alnylam Pharma

For some perspective on what is possible for NTLA at a market cap of $1.25 billion, let's visit one of my success stories in the Healthcare Innovators portfolio, the $42 billion Alnylam (ALNY). Here's what I told our members recently...

Our ALNY has surged recently after a year-long consolidation because the market is very receptive to its RNA-interference treatment for ATTR. In March, Amvuttra (vutrisiran) was cleared as a quarterly injection to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart, potentially causing the organ to fail. I did a deeper dive on this in March.

Amvuttra works by silencing the production of the disease-causing protein and relies on a much less invasive administration of a subcutaneous injection every 3 months.

This advance was on the back of success with a similar treatment, Onpattro (patisiran), which required an intravenous infusion every 3 weeks.

Yesterday, one of my favorite Biotech analysts, Michael Yee of Jeffries, raised his price target on ALNY to $384.

The Intellia Incursion

Meanwhile for Intellia, there have been high hopes and dashed hopes to build a reliable platform in ATTR, securing both efficacy and safety. So we've had a tough run trying to stay long this CRISPR stock, and I've forgotten half of the setbacks the company has faced in and out of the pipeline.

So I asked Perplexity for some help there, which you can find below after I go over my bullish catalysts...

Cooker's Tailwinds

1. Gene editing peers CRSP and BEAM have recovered after Eli Lilly (LLY) made a bid to acquire Verve Therapeutics (VERV) for as much as $1.3 billion (a nearly 100% premium). LLY really got a deal here for this cardiovascular-focused platform (most analysts had price targets near $25 not $11) and I would expect other big pharma to be shopping for these key future gene editing assets/lotto tickets while they are still on sale.

2. Our Alnylam (ALNY) has surged recently after a year-long consolidation because the market is very receptive to its treatment for ATTR. My colleague Mayur Thaker, who also studies these companies and their platforms, believes that the Intellia approach is superior and will eventually win the day. That's the kind of asymmetric trade I like in Biotech.

3. NTLA shares are forming a base between $7 and $10 for the past 6 months, with recent volume accumulation every week of June. Institutional buying in the March quarter was strong, with a new 3.8 million share position from Capital International Investors. And of course, Cathie Wood's ARK Invest is on top with 13 million shares. I expect to see more buying when we get the next SEC 13Fs in August.

Setbacks Faced by Intellia Therapeutics in Recent Years (exact prompt I gave Perplexity)

>>Program Discontinuations and Pipeline Cuts

NTLA-3001 Discontinuation: Intellia halted development of NTLA-3001, an in vivo gene insertion therapy for alpha-1 antitrypsin deficiency (AATD)-associated lung disease, in early 2025. This decision was part of a broader strategic reorganization to focus resources on late-stage programs with higher near-term commercial potential.

Other Research-Stage Program Cuts: Alongside NTLA-3001, Intellia discontinued select early-stage and preclinical programs, including NTLA-2003 for AATD-associated liver disease, as part of ongoing portfolio prioritization.

Workforce Reductions: The company executed significant layoffs—cutting 27% of its workforce in 2025 and 15% in 2024—to align with its narrowed pipeline and manage costs in a challenging funding environment.

>>Clinical and Safety Setbacks

Safety Concerns in MAGNITUDE Trial (nex-z): In May 2025, a participant in the Phase 3 MAGNITUDE study for nexiguran ziclumeran (nex-z) experienced grade 4 liver transaminase elevations, a sign of significant liver stress. Although the event resolved without hospitalization, it raised safety concerns and triggered a sharp drop in Intellia's share price.

>>Strategic and Competitive Challenges

Loss of Sickle Cell Program Partnership: Novartis discontinued development of an ex vivo sickle cell disease program partnered with Intellia, reflecting a shift in strategic focus and impacting Intellia's ex vivo ambitions.

Market and Funding Pressures: The company faced a tough biotech funding climate, necessitating portfolio streamlining and cost controls to extend its cash runway until anticipated product launches.

>>Leadership Changes

Executive Turnover: The retirement of Chief Scientific Officer Laura Sepp-Lorenzino in 2025, with a new CSO appointed, marked a significant leadership transition during a pivotal period for the company.

Expected Data Readouts and Pipeline Developments for Intellia

As always in Biotech, every data readout and pipeline development is a binary event. It could send shares soaring or crashing. But the risk is relatively low here and so we want to be buyers of dips back under $10.

Here are some of the pipeline events we want to be watching for as Intellia is advancing commercialization and medical capabilities in anticipation of its first U.S. launch:

1. NTLA-2002 (Hereditary Angioedema, HAE)

Phase 3 HAELO Trial: Enrollment for this pivotal study is expected to complete in the second half of 2025. The company plans to submit a Biologics License Application (BLA) in the second half of 2026.

Phase 1/2 Study Data: Additional, longer-term durability data from the Phase 1 portion will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in June 2025. Updated Phase 2 data, including patients who transitioned to the 50 mg dose, will be presented in the second half of 2025.

2. Nexiguran Ziclumeran (nex-z, formerly NTLA-2001; Transthyretin Amy-loidosis, ATTR) Phase 3 MAGNITUDE and MAGNITUDE-2 Trials

Enrollment in the global MAGNITUDE trial for ATTR with cardiomyopathy (ATTR-CM) is progressing ahead of schedule, with over 550 patients expected by year-end 2025.

The first patient was dosed in the pivotal MAGNITUDE-2 trial for ATTR with polyneuropathy (ATTRv-PN) in Q1 2025.

Longer-Term Phase 1 Data: New two-year follow-up data for nex-z in ATTRv-PN show a sustained 90% reduction in TTR protein and clinically meaningful improvements in neuropathic impairment measures. This includes patients who had previously progressed on patisiran, with results presented at the 2025 Peripheral Nerve Society (PNS) Annual Meeting.

Upcoming Data: Additional longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study—including updated efficacy and safety measures—are expected in the second half of 2025.

3. Pipeline Focus and Other Programs

Strategic Pipeline Prioritization: Intellia has discontinued NTLA-3001 and is focusing resources on NTLA-2002 and nex-z for efficient execution and near-term value creation.

CRISPR Jumps On Big Insider Buy

On July 18, I shared this update with our members...

Healthcare Investor

CRISPR Therapeutics (CRSP) shares were flying high this morning, up over 20% at one point.

The likely catalyst was news of a member of the Board of Directors buying $51.5 million worth of shares.

Not a small purchase. And not something a Biotech insider does unless he knows something good is coming.

Director Simeon George, on July 16, 2025, executed a purchase for 989,812 shares in CRSP for $51,499,918. Following the Form 4 filing with the SEC, George has control over a total of 1,730,179 common shares of the company.

Looks like he was probably worried about the stock getting away last week on the rally to nearly 52-week highs above $60, so he grabbed the pullback under $55 with gusto!

And Cathie Wood remains as bullish as ever too, adding 1.2 million shares in the March quarter to bring her haul over 10M.

Our Stable Looks Good

Since adding NTLA last week, all of our CRISPR wing has turned green. Let's look at the drivers...

Drivers of Recent Recovery in CRISPR Companies (CRSP, BEAM, NTLA)

Several key factors are fueling the recent rebound in CRISPR-focused biotech stocks:

Clinical Breakthroughs and Positive Data: CRISPR Therapeutics (CRSP) reported strong early-stage results for its in vivo gene editing therapy CTX310, showing significant reductions in LDL and triglycerides. This success, along with positive updates on other pipeline candidates, has boosted investor confidence.

First-in-Human Personalized CRISPR Therapies: Landmark cases, such as the successful discharge of the first infant treated with a personalized CRISPR therapy, have demonstrated the real-world potential and safety of gene editing, energizing the sector and validating the technology's promise.

Market Expansion and Commercial Progress: The launch and expanding access to CRISPR-based therapies like Casgevy for sickle cell disease and beta-thalassemia, with more treatment centers coming online, signal growing commercial traction.

Pipeline Momentum and Anticipated Readouts: All three companies—CRSP, BEAM, and NTLA—are expected to deliver multiple clinical readouts in 2025, maintaining investor interest and optimism for future approvals and applications.

Industry Growth Trends: The CRISPR gene editing market is projected to grow rapidly, driven by increased demand for genetic therapies, technological advances, and broader adoption in medicine.

We are catching another revival in CRISPR and we are in at good levels. Let's see if this is the final kiss goodbye to the CRISPR bear and more investors start paying attention to the clinical data at such low valuations.

(end of Healthcare Innovators note to members on July 18)

Bottom Line

While AI has stolen the show for the biggest industrial and scientific development of the decade, I still believe it is the "Century of Biology" and that investors should stay exposed and keep looking for hidden gems that could be part of the success stories in treating disease and improving lives with massive benefits vs the costs.

Kevin Cook – Editor of Healthcare Innovators and TAZR

VirTra, Inc.

It's an exciting time in the stock market right now with the major U.S. indexes eclipsing their former all-time highs (at the time of this writing). As we make our way into the third quarter, let's take a step back and try to determine what may lie ahead for the rest of 2025 and beyond.

It was certainly a first half to remember. The see-saw action translated to one of the most volatile first halves in recent memory. President Trump's tariff agenda sent shockwaves throughout the financial markets, resulting in a nasty correction earlier in the year as investors priced in potential trade outcomes.

By April, market performance began to turn the corner, improving rapidly as investors gained more clarity amid signs of trade-talk progress. The V-shaped, relentless move morphed into a lockout rally that left nonbelievers in the dust. And because many investors missed out on big gains, they will continue to snap up shares on weakness, which should help lift stocks even further.

The S&P 500 just delivered one of the greatest three-month rallies in history, advancing more than 25% off the April lows. As we can see below, the blue-chip index has only accomplished this feat five other times since its inception in 1957.

Recent Rally Points to More Strength Ahead

S&P 500 Forward Returns Following 3-Month +25% Move

Year of S&P 500 3-Mo. 25% Rally	S&P 500 1-Yr. Change
1975	18%
1982	20%
1999	12%
2009	19%
2020	39%
Average	21%

As we can see, in the twelve months following each of these instances, the S&P 500 delivered double-digit gains each time. As the saying goes, strength begets strength.

Still, the doubters and naysayers remain prevalent. This is certainly one of the most hated market rallies since the surge in stocks following the onset of the COVID-19 pandemic. There are always reasons that critics can point to as to why stocks can't continue higher, but as we know, stocks climb a wall of worry.

On the positive side, the earnings outlook remains strong, with the U.S. consumer proving healthy and resilient. Inflation measures continue to show significant signs of deceleration. And a bullish artificial intelligence theme has triggered strength in the aggressive pockets of the market, such as information technology, electronics and communication services.

Knowing this, we want to target stocks that have entered uptrends but still have room for significant appreciation. The recent passing of Trump's "One Big Beautiful Bill" will result in substantial increases in military spending, law enforcement, and related applications. It is with this underlying premise that I present my stock pick.

VirTra (VTSI) is a global provider of use-of-force training and firearms training simulators for law enforcement, military, and commercial markets. VirTra has all the characteristics we look for, including positive earnings estimate revisions, the backing of a leading industry group, and strong sales trends. As we'll see, buying pressure in this stock is beginning to increase, paving the way for VTSI shares to double or more in price.

Zacks Rank and Industry Group Analysis

A Zacks Rank #1 (Strong Buy) stock at the time of this writing, VirTra is a component of the Zacks Electronics - Military industry, which ranks in the top 1% out of approximately 250 industry groups. Because it is ranked in the top half of all Zacks Ranked Industries, we expect this group to outperform over the next 3 to 6 months.

The stocks within this industry group are experiencing positive earnings estimate revisions, which is the most powerful force impacting stock prices. We can see the steady outperformance off the April lows:



Source: Zacks.com

Quantitative research studies suggest about half of a stock's future price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries outperforms the bottom 50% by a factor of more than 2 to 1.

It's no secret that investing in stocks located within the top industries can offer a boost to portfolio returns. Investing in stocks within leading industry groups provides a constant tailwind to our investing results. By focusing on leading stocks within the top 50% of Zacks Ranked Industries, we can dramatically improve our stock-picking success.

The Underlying Business

VirTra's patented technologies and software provide training for de-escalation, judgmental use-of-force, and marksmanship scenarios that mimic real-world situations. Its V-300 simulator is a 300-degree wrap-around screen for simulation training, while its V-180 simulator is designed for smaller spaces and budgets.

In addition, VirTra's V-100 is a single-screen based simulator system, while its V-ST PRO aims for a realistic firearms shooting and skills training simulator. The company also provides Virtual Interactive Coursework Training Academy (V-VICTA), which enables law enforcement agencies to teach, train, and test departmental requirements.

VirTra's mission is to keep police officers and military servicemembers safe. The military solutions provider sells its simulators and related products through a direct sales force and distribution partners. It was founded in 1993 and is headquartered in Chandler, Arizona.

Recent Earnings and Future Forecasts

VirTra has exceeded the earnings mark in three of the past four quarters, sporting an average beat of 199% over that timeframe. The company most recently delivered first-quarter earnings results back in May of 11 cents per share, a 1,000% surprise over the $0.01/share consensus estimate. Consistently beating earnings estimates by a wide margin is a recipe for outperformance.

For the current year, analysts have increased earnings estimates by 58.82% in the past 60 days. The 2025 Zacks Consensus EPS Estimate now stands at 27 cents per share, which reflects a staggering +125% growth rate versus last year.

Magnitude Consensus Estimate Trend (60 Days)

	Q1	Q2	F1	F2
Current	0.03	0.05	0.27	0.38
7 Days Ago	0.03	0.05	0.27	0.38
30 Days Ago	0.03	0.05	0.27	0.38
60 Days Ago	0.03	0.05	0.17	0.38
Trend of Estimate Revisions:	0%	0%	+58.82%	0%

Source: Zacks.com

In terms of revenue growth, VirTra looks to increase revenues by nearly +8% this year to $29.2 million, with analysts anticipating additional growth of over +20% in 2026 to $35.1 million.

Sales are one of the most important metrics to focus on, as growth in sales can tip off investors to a potential accumulation phase and significant share price appreciation.

Technical Evaluation

The correction earlier this year created an incredible opportunity in VTSI shares. The stock has soared more than +70% off the lows, with buying pressure beginning to manifest itself.



Chart courtesy of StockCharts.com

Unlike big tech, VTSI stock does not appear to be extended in the short-term. The stock has risen above both its 50-day (blue line) and 200-day moving average (red line), signifying an important trend change.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. And as we know, VirTra has seen a recent batch of positive revisions. As long as this trend remains intact (and VTSI continues to deliver earnings beats), the stock should continue its strong momentum into the second half of the year.

Bottom Line

Buoyed by a leading industry group with above average projected earnings growth, it's not difficult to see why VirTra stock is set to double. With strong fundamentals and an evolving technical picture, it's clear that shares have room for significant advancement.

Historical statistics point to more general market strength in the second half of this year, which should help propel VTSI shares further.

The Zacks Rank #1 (Strong Buy) stock is expected to flourish in the near future. Its military training software is witnessing a surge in usage and is a best-in-class platform. A history of positive earnings surprises along with robust revenue growth certainly warrant a closer look at this company.

Bryan Hayes, CFA – Editor of Headline Trader and Income Investor

Nebius Group N.V.

There are several things that have to happen for a stock to double. One of the most important being revenue growth. Having revenue growth is a great first step, but I have learned over the years that it is not that great if no one knows about it.

The other thing you need is a stock in a hot industry that is experiencing a lot of investor demand. Investors need to be attracted to the space in general, which will push them to dig into a company that they ordinarily might not look at. Maybe it is a smaller stock, a stock that is traded in Europe, or run by a Russian Oligarch. Whatever the case, we buy stocks with the hopes that they will double and then some.

Right now, the AI space is booming and there are some very big early leaders that have already captured some huge gains. The thing is, there will be more winners and they won't all come from the United States. Sometimes we have to look abroad for stocks that stand a chance to really outperform.

Nebius Group (NBIS) is a one of the companies in the AI ecosystem and the attention in the sector is only going to grow. The company is rather young, but is already making waves in the sector and could become a dominant player in Europe.

NBIS is an AI centric cloud platform built for intensive AI workloads. The company builds full stack infrastructure for AI, including large space GPU clusters, cloud platform tools, and generative tools for AI development. That is basically all the buzzwords you need to see when looking for the next big AI stock.

AI Build Out Continues

We are in the very early stages of the AI cycle and that means that there is a race to build the infrastructure needed to house AI data, and the components needed to make the leap to true AI. First movers are already seeing a big advantage as they are learning from their early missteps and fine tuning their data collection and processes as they push to profitability.

Being early in a cycle like this requires one basic investment tenant, you have to be patient. The build out is still going strong and we measure this in terms of CapEx from the big tech names. They need to continue to invest in the infrastructure to be able to meet the demand for the AI services that are almost inevitable at this point.

Enter Demand

We are very early in the adoption of AI, but the recent earnings reports suggest that demand will be very strong. This could be a fundamental change to how businesses are managed and that means the services provided will be in high demand.

We have already seen great results from the early adopters that would be considered low hanging fruit from the customer base. Think of the programmatic advertisers that use formulas to decide where and when to run commercials for their clients. This was almost a version of AI, but now with a richer data set, better speed, and more analysis, a better decision can be made.

The AI boom will really start to show results when the next level of customers start to show the positive results of AI integration. This could only be a couple of quarters away.

Growth

NBIS already has demand for its services, but they will likely continue to grow.

In 2025 analysts estimate revenue will be $588M, which represents growth of +401%.

In 2026, the estimates continue to move higher. I see revenue estimates at $1.5B, which would be good for growth of +155%. Considering that estimate is about a year and a half away, there is a good chance that we could see that number move even higher.

The June quarter is projected to see $95M in sales, up from $85M just a few months ago. The September quarter has revenue estimates of $170M, which is nearly a +100% increase from the level that is expected to be reached just 90 days prior. That sort of growth is going to attract a lot of attention.

Valuation

The rubber always seems to meet the road when investors look at the valuation of a company. At the time of this writing, NBIS was not making money so there is no forward PE.

The price-to-book multiple of 4X is very low. This will attract value investors as they typically look for stocks with a lower price-to-book multiple. Having both growth investors and value investors checking their respective boxes is another key factor in why this is a stock that could potentially double.

Price-to-sales at 1.6X is also very low for a company that is expected to show +401% revenue growth.

Right now, the margins are not that impressive, but over time as the company grows its client base, then there will be opportunities to raise prices and increase margins.

Bottom Line

Having growth is not a panacea for a sure-fire stock that will double. NBIS is in a hot space and looks to have several more customers over the next several quarters. Another key aspect that will help propel NBIS to double is the low valuation, as it will still attract a lot of investment even when the price-to-book multiple is 50% to 100% higher. The other idea is the low price to sales multiple will really help the stock rise when the September quarter comes in and the growth becomes apparent to those who are not already following this stock.

Brian Bolan – Editor of Home Run Investor and Stocks Under $10

Bitcoin Depot Inc.

Want a way to own Bitcoin while at the same time getting a business that is generating strong free cash flows and growing earnings?

You can do it with the fintech company, **Bitcoin Depot (BTM)**.

It operates the largest Bitcoin ATM network in North America with over 8,500 locations and a growing international presence.

But what does that have to do with actually owning Bitcoin? In 2024, Bitcoin Depot announced a strategy to buy Bitcoin with some of its extra cash.

It now owns "over" 100 BTC in addition to its cash on hand.

Traders have discovered Bitcoin Depot in 2025. Shares have more than doubled this year, but it's still cheap with low price-to-earnings and price-to-sales ratios.

Bitcoin Depot is a rare value stock that also has growth, and you get some Bitcoin too.

Bitcoin Depot Expands its U.S. Reach

Bitcoin Depot was founded in 2016, which seems like forever ago when it comes to cryptocurrencies. Yet it is still a small-cap company with a market cap of just $355 million. It has a nationwide expansion strategy to grow its industry-leading ATM network.

On June 11, 2025, it announced it was acquiring Pelicoin, LLC, a crypto ATM operator based in New Orleans, LA. Pelicoin had a big presence across the Gulf South, with kiosk locations across Louisiana, Mississippi, Tennessee, Alabama, and Texas.

After the deal closed, all of Pelicoin's kiosks were converted to Bitcoin Depot kiosks. Pelicoin touted Bitcoin Depot's 24/7 customer service and other services that only a larger operator could provide as a key incentive for the deal.

Financial terms were not disclosed.

Bitcoin Finally Sees Positive Earnings in 2025

But Bitcoin was already turning the business around even without acquisitions.

On May 15, 2025, Bitcoin Depot reported its first quarter results. Earnings came in at $0.20, easily beating the Zacks Consensus of $0.09. But the quarter was significant for several reasons, including healthy revenue and free cash flow growth.

Revenue was up +19% to $164.2 million year-over-year with adjusted gross profit surging +92% to $33.1 million. The revenue gain was due to increased kiosk deployment and higher median transaction size.

Net cash flows provided by operations in the quarter jumped to $16.3 million from $1.3 million a year ago.

Analysts are Bullish on Bitcoin Depot in 2025 and 2026

Even though Bitcoin Depot is a small-cap company, which are normally lightly covered, Zacks has four analyst estimates for this year. Analysts are paying attention.

Analysts are looking for $0.46 in 2025 after Bitcoin lost $0.60 last year. That's earnings growth of 176.7%.

2026 is also bullish with the Zacks Consensus calling for $0.51. That's another 10.3% earnings growth.



Source: Zacks.com

Lots of Cash, and Bitcoin, on Hand

With profitability improving, the company's cash, cash equivalents and cryptocurrencies, as of Mar 31, 2025, were $43.3 million, up from $31 million at the end of 2024.

Bitcoin Depot used some of the cash, $7.8 million, to acquire 83 more Bitcoin in the quarter, bringing the total held for investment as of May 15, 2025, to 94.35 BTC.

But as of June 13, 2025, that number had grown to "over" 100 BTC.

The company is expected to report second quarter earnings in late August, so there will be an update on all the cash and Bitcoin holdings then.

Investors Are Keyed into the Bitcoin Depot Story, but Shares Are Still Cheap

The stock has already doubled this year, but it was a stock under five dollars when the turnaround in earnings began.

Yes, traders have been trading this stock. It's volatile.

Source: TradingView

But it's still cheap based on the fundamentals.

Bitcoin Depot has a forward price-to-earnings (P/E) ratio of just 12.1. A P/E ratio under 15 usually indicates a company has value.

It also has a price-to-sales (P/S) ratio of just 0.2. A P/S ratio under 1.0 can mean a company is undervalued. Investors are getting $1.00 worth of sales for just 20 cents. They are getting the sales on sale.

And then there is the value of the Bitcoin holdings as it hits new highs. Of course, Bitcoin could go the other way and sell-off too. But while it's on the rise, that is a growing asset on the company's balance sheet.

Bitcoin Depot is growing and is generating a nice amount of cash. It's finally seeing some real earnings.

Bottom Line

For those looking for a Bitcoin and fintech play in one company, and are looking for a small-cap stock, Bitcoin Depot should be on your short list.

Tracey Ryniec - Editor of Insider Trader and Value Investor

Evolv Technologies Holdings, Inc.

When you're on the hunt for the next stock to double, there are many factors to take into account. Chief among them is growth. Ideally, you want to find a stock with great earnings growth forecasts within an industry that is growing leaps and bounds. Nowadays, and for the last couple decades, those characteristics have shown up in tech.

Technology companies disrupt by nature. They take old industry models and flip them on their heads. There are very few new technologies that are as disruptive as AI. Apply this disruption to the old-school security business and you have a winner. That's exactly where I'm going with my next stock to double.

Evolv Technologies (EVLV) is stealthily arming venues around the globe with next-generation AI-driven weapons-detection systems, and yet its shares trade at a fraction of what you might expect for a company transforming the multi-billion-dollar security screening industry. While most investors yawn at "security as a service," Evolv is quietly converting that yawner into a blockbuster, and here's why you should be piling into EVLV before the rest of Wall Street figures out the punchline.

A Market Ripe for Disruption

Traditional metal detectors have guarded our stadiums, convention centers, and schools for decades, but they're slow, cumbersome, and trigger on anything with a metal clasp, including your grandma's reading glasses. Evolv's AI-powered platform, anchored by its flagship Evolv Express system, ignores harmless items while detecting concealed firearms and knives in real time.

This touchless, high-throughput approach is gaining traction not only for efficiency but also for public health, as the pandemic shifted minds toward contactless solutions. In 2024 alone, global security screening spend topped $5 billion, with a projected CAGR of over 7% through 2028. Evolv sits squarely at the intersection of security and AI disruption. These are two mega-themes investors love.

Accelerating Revenue Trajectory

Evolv's growth engine roared to life in Q1 2025, posting revenue of $32.0 million, a +44% year-over-year increase from $22.2 million in Q1 2024. Even more impressive, Annual Recurring Revenue (ARR) climbed to $106 million, up +34% from $79.2 million a year earlier. This rapid climb in ARR reflects not just one-time hardware deployments, but a sticky subscription backbone, indicating that once customers plug in Evolv's sensors, they're inclined to renew, which is helping to drive predictable, high-margin revenue streams.

Losses are narrowing faster than a train on a down-hill track. Q1's net loss shrank to $1.7 million (-5% net margin) from $11.3 million a year ago (-51% margin). Adjusted EBITDA turned positive at $1.7 million, flipping from a $10.4 million loss in Q1 2024. In plain English, Evolv isn't just growing sales; it's learning to turn profits. With positive EBITDA and a path to breakeven as revenue scales, investors get to ride the growth wave without permanent red ink.

A Bullet-Proof Balance Sheet

Cash is king, but debt is the sneaky backstabber. Evolv's treasury boasts $35 million in cash and marketable securities, with zero debt as of March 31, 2025. That's enough dry powder to fund expansion initiatives, like opening new international sales channels or investing in R&D, without begging the capital markets for more equity (which would dilute shareholders). A debt-free balance sheet in a capital-intensive biz is akin to finding a unicorn in a parking lot.

Management's 2025 outlook calls for revenue of $125-130 million (up +20-25% year-over-year) and positive full-year Adjusted EBITDA, even after earmarking $2 million in process-enhancement investments. Wall Street's taking notice: Northland and Craig-Hallum both bumped their price targets to $8.25, implying roughly 40% upside from EVLV's current ~$5.83 share price. With a forward P/S multiple still in single digits, Evolv is trading like a garage-startup, not a growth leader in a nascent multibillion-dollar industry.

There's No 'Mentum Like Momentum

Investing isn't just about fundamentals; momentum can ignite its own rocket fuel. Following the Q1 beat, EVLV spiked +6.3% in after-hours trading, closing at $5.89. Over the past six months, shares have surged more than +120%, handily outpacing the Nasdaq's +20% climb. And yet, even with this impressive sprint, the stock hasn't sprinted so far that it's toppled past a reasonable valuation, giving nimble investors a chance to buy into enthusiasm that's still got room to run.

Source: TradingView

Shares bottomed out on Liberation Day down at $2.64. Since then, the stock has more than doubled. From a technical standpoint, the 50-day moving average just provided a ton of support, helping a two-day rally to recent highs. Volumes have increased as well, clueing us in on increased interest all around Wall Street. Put simply, the stock is on the map.

Evolv's systems aren't a one-trick pony for stadiums; they're emerging at schools, corporate campuses, hospitality venues, and transit hubs. As security budgets swell in the face of rising global threats, organizations in every vertical are looking for solutions that balance safety with guest experience. Evolv's footprint now spans over 6,600 subscriptions globally, up from just a few hundred two years ago. This diversity insulates the company from downturns in any single sector, whether it be entertainment, education, or enterprise.

The company isn't resting on its laurels. The recent launch of the Expedite autonomous bag-screening solution accelerates throughput even further, while the Certified Pre-Owned program opens a new ladder for cost-sensitive customers. Each new product enhances the "land-and-expand" playbook, turning one-off hardware deals into multi-year software subscriptions. In an industry where flip-a-switch installations can cement relationships, Evolv's continual pipeline of enhancements ensures customers remain "sticky" and spend more per site over time.

Risks Are Priced In—But Still Manageable

Yes, Evolv operates in a competitive landscape, including analog players and new AI startups, and large enterprise sales can be drawn out by RFPs and budget cycles. However, the company's track record of beating revenue forecasts and meeting ramp-ready milestones suggests management's execution chops are solid.

Bear in mind that most customer rollouts require capital expenditure decisions and security committee approvals. These barriers actually slow competitors more than incumbents, giving Evolv a first-mover edge.

Bottom Line

Evolv Technologies checks all the boxes that tickle the fancy of savvy growth investors: blistering top-line growth, a rapid path to positive operating cash flow, a debt-free balance sheet, strong analyst backing, and a stock momentum story that still has room to run. For those seeking exposure to the broader AI Revolution, Evolv provides a pure-play on intelligent automation in security screening, an area poised for secular tailwinds as the world continues to prioritize safety and seamless experiences. That's why I'm naming Evolv Technologies as my next Stock to Double.

David Bartosiak – Editor of Blockchain Innovators and Surprise Trader

What To Do Next

In addition to the information included in this special report, you can move yourself way ahead of the crowd in any market environment with the following items.

1.) As part of this report, you will now receive our daily e-newsletter, ***Profit from the Pros.***

- Each morning, Executive Vice President Kevin Matras will summarize the market, what it means for investors and what to do next. Plus, you get links to articles featuring some of our top stock, ETF, and mutual fund recommendations.

  Be sure to look for it in your email inbox before the market opens every day.

2.) You should **bookmark our homepage** to take advantage of one of the most complete investment websites around.

- Go there now: www.zacks.com

3.) Even better, get all Zacks' private buys and sells through our ***Zacks Ultimate*** program.

- Watch our trades and market insights from all of Zacks' private portfolios from growth to value to momentum stocks, from insider moves to big earnings surprises, from options to ETFs, even trades EVP Kevin Matras makes in his personal account, and much more. This see-everything arrangement is unique: one month, one dollar, not one cent of further obligation.

  Learn more about the *Zacks Ultimate* now »

Disclaimer

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company names represented herein are trademarks of Intellia Therapeutics, Inc.; CRISPR Therapeutics AG; Alnylam Pharmaceuticals, Inc.; Beam Therapeutics Inc.; Eli Lilly and Company; Verve Therapeutics Inc.; VirTra, Inc.; Nebius Group N.V.; Bitcoin Depot Inc.; Evolv Technologies Holdings, Inc. Front cover source: Shutterstock

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service". www.zacks.com/terms_of_service

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or U.S. investment adviser or investment bank.

The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through July 7, 2025. The performance is the equal weighted performance of a hypothetical portfolio consisting of stocks with a Zacks Rank of #1 that was rebalanced monthly from January 1988 through December 2013 and weekly from 12/31/13 through Monday's open on July 7, 2025. For each stock with a Zacks Rank #1 at the beginning of the month, the total return during the month was calculated as the % change in the price of the stock from the closing price of the prior month to the closing price of the current month plus any dividends received during the month. The monthly individual stock returns were then averaged to determine the portfolio return for the month. For each stock with a Zacks Rank #1 at the beginning of the week, the total return during the week was calculated as the % change in the price of the stock from the opening price for the week to the opening price of the next week plus any dividends received during the week. The weekly individual stock returns were then averaged to determine the portfolio return for the week. If no month-end price or week end open price was available for a stock, it was not included in the portfolio return for the month or the week. The monthly and weekly returns were compounded to arrive at the annual returns. The annualized return is the annual return that, had it been achieved in each year or portion of a year, would have compounded to create the total return over the full time period. These returns are based on the list of Zacks Rank #1 Stocks that was available to clients of Zacks as of the beginning of the month, when returns were calculated monthly, or as of the beginning of the week when returns were calculated weekly. These returns are higher than the returns an investor could achieve investing real money in a portfolio of Zacks Rank #1 stocks because the returns of the hypothetical Zacks Rank #1 portfolio exclude a number of costs, including commissions incurred for trading, the average bid ask spread, the price impact of the trading and, prior to 2013, in those months when the end of the month fell on Friday, Saturday or Sunday, the overnight return from the month end close to the open on the next trading day. The S&P 500 is an unmanaged index. Visit www.zacks.com/performance_disclosure for information about the performance numbers displayed above.